Cargando…
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
BACKGROUND: Bromodomain and extra-terminal domain inhibitors like JQ1 have proved to be promising epigenetic agents for the treatment of malignant ovarian carcinoma. However, the resistance of ovarian cancer cells to BET inhibitors has not been elucidated. In this study, we investigated the potentia...
Autores principales: | Luan, Wenqing, Pang, Yingxin, Li, Rui, Wei, Xuan, Jiao, Xiaoxiao, Shi, Juanjuan, Yu, Jiangtao, Mao, Hongluan, Liu, Peishu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781612/ https://www.ncbi.nlm.nih.gov/pubmed/31632060 http://dx.doi.org/10.2147/OTT.S220267 |
Ejemplares similares
-
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
Publicado: (2019) -
The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
por: Pang, Yingxin, et al.
Publicado: (2022) -
ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo
por: Li, Rui, et al.
Publicado: (2019) -
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021) -
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021)